Tumour treating fields (TTFields), alternating electric fields delivered via transducer arrays placed on the scalp, have emerged as a new modality of treatment for glioblastoma (GBM), with studies showing improved survival in patients with newly diagnosed or recurrent disease. New data presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US, provide insights into its use in GBM treatment.
Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) more than halved their risk of dying or developing distant metastasis when treated with darolutamide in addition to androgen deprivation therapy (ADT), according to findings of the phase III ARAMIS* trial.
The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.